Tirzepatide Eligibility: Biomarkers, Genetics & Who Can Use It

Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Not everyone is a candidate for tirzepatide, though eligibility extends beyond a simple BMI threshold. Medical history, kidney function, thyroid status, and individual metabolic markers all influence suitability and potential outcomes.

PlexusDx emphasizes precision-wellness: understanding your unique biomarker profile and genetic predispositions in peptide pathways can help support a more personalized eligibility conversation with your provider—moving beyond one-size-fits-all assumptions toward data-informed care.

Core Eligibility Criteria and Medical History Factors

Tirzepatide is approved for weight management in adults with obesity or overweight with at least one weight-related condition. However, approval is just one lens; medical history, current medications, and organ function matter significantly for real-world candidacy.

Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, uncontrolled type 2 diabetes with acute complications, and active gallbladder disease. Kidney and liver function also influence dosing and monitoring needs.

Biomarker Assessment and Metabolic Risk Profiling

Baseline biomarkers—fasting glucose, HbA1c, kidney function (eGFR), liver enzymes, and lipid panels—provide clinical context for tirzepatide suitability. These markers help identify which patients may benefit most and which may require closer monitoring or dose adjustments.

Biomarker	Relevance to Tirzepatide Use
Fasting Glucose & HbA1c	Reflects baseline glucose control; high levels may indicate metabolic dysfunction responsive to tirzepatide dual-agonist mechanism.
eGFR (Kidney Function)	GFR <30 may require dose adjustment or avoidance; eGFR 30–60 warrants caution and closer monitoring during treatment.
Liver Enzymes (ALT/AST)	Baseline elevation suggests hepatic stress; tirzepatide use requires periodic monitoring to detect rare but serious hepatic effects.
Fasting Triglycerides	High triglycerides reflect lipid dysfunction tirzepatide may improve; baseline level helps assess treatment response trajectory.

Genetic Predispositions and Peptide Pathway Response

Genetic variants in GLP1R and GIPR genes influence how individuals respond to tirzepatide at the molecular level. The Precision Peptide Genetic Test reveals predispositions in these pathways, which may help contextualize individual eligibility and expected response patterns.

A patient with favorable GLP1R rs6923761 or GIPR rs1800437 variants may theoretically experience stronger appetite signaling modulation, while variants in FTO and MC4R genes relate to metabolic rate and satiety regulation. These predispositions should be interpreted with a qualified provider to inform realistic expectations.

Who Should Avoid Tirzepatide and When Monitoring Is Essential

Absolute contraindications include personal or family history of medullary thyroid cancer and MEN2. Patients with acute pancreatitis, severe diabetic retinopathy, or ongoing gallbladder issues should consult providers before initiation; pregnancy or breastfeeding requires discontinuation.

Ongoing monitoring—kidney function every 6 months, thyroid ultrasound screening in high-risk individuals, and regular appetite/satiety symptom assessment—ensures safety. Providers should also evaluate drug-drug interactions, particularly with insulin or sulfonylureas, which may increase hypoglycemia risk.

How PlexusDx Supports a More Personalized Approach

PlexusDx's approach to tirzepatide eligibility integrates biomarker context and genetic predisposition screening. The Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R that may help provide context for how your metabolic and appetite-control pathways function—supporting a more informed eligibility discussion with your provider.

The genetic test reveals predispositions in peptide signaling pathways, but does not predict exact medication response or guarantee outcomes. Variants interact with environment, diet, adherence, and other medications in complex ways. Results should be interpreted with a qualified healthcare provider alongside clinical biomarkers and medical history.

Combining genetic insights with baseline kidney function, glucose control, thyroid status, and liver health can support a more personalized conversation about whether tirzepatide aligns with your risk profile and treatment goals. PlexusDx compounded tirzepatide options (from licensed 503A pharmacies) allow flexibility in dosing and formulation as providers optimize eligibility and response.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.